Pfizer, Inc. vs Regeneron Pharmaceuticals, Inc. — Stock Comparison
Pfizer, Inc. (PFE) and Regeneron Pharmaceuticals, Inc. (REGN) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Regeneron Pharmaceuticals, Inc. clearly outscores Pfizer, Inc. on Q·Score (8.5 vs 6.2 out of 10), led by Health (9.7 vs 7) and Quality (8.8 vs 6.4). Analyst consensus targets imply greater upside for REGN (+36.1%) than for PFE (+11.4%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consistently beats earnings estimates (4/4 quarters).
⚠ earnings contracting 10% year-over-year.
Clean balance sheet with low leverage (0.1× debt-to-equity).
Analyst Consensus
Fundamentals
Frequently Asked Questions
PFE vs REGN: which stock scores better overall?
Based on Q·Score, Regeneron Pharmaceuticals, Inc. (REGN) scores 8.5/10 versus Pfizer, Inc. (PFE) at 6.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: PFE or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Growth (7.3/10 vs 5.1/10). Pfizer, Inc. reports revenue growth (5.4% YoY) while Regeneron Pharmaceuticals, Inc. reports (19.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is PFE or REGN more attractively valued?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Valuation (8.7/10 vs 7/10). PFE trades at 9.3× P/E versus REGN at 11.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about PFE vs REGN?
There are 27 analysts covering PFE with a consensus price target of $29.19, and 28 analysts covering REGN with a consensus target of $833.31. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: PFE or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Quality (8.8/10 vs 6.4/10). Net profit margin: PFE at 11.8%, REGN at 29.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: PFE or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Financial Health (9.7/10 vs 7/10). Market beta: PFE at 0.29, REGN at 0.24. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of PFE and REGN?
Pfizer, Inc. (PFE) has a market capitalisation of $149.4B, while Regeneron Pharmaceuticals, Inc. (REGN) has a market cap of $64.2B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do PFE or REGN pay dividends?
PFE pays a dividend yield of 6.56%, while REGN pays a dividend yield of 0.61%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →